Amicus Therapeutics, Inc. (FOLD) Expands Pipeline With Rare Kidney Disease Drug

We recently published 10 Best Biotech Stocks to Buy Under $10. Amicus Therapeutics, Inc. is one of them.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) tops our list for being one of the best biotech stocks. It develops therapies for rare diseases, including Fabry disease and late-onset Pompe disease. Its flagship products include Galafold, an oral precision medicine for Fabry disease, and the combination therapy Pombiliti + Opfolda for Pompe disease.

The company recently acquired DMX-200, a candidate targeting focal segmental glomerulosclerosis (FSGS), broadening its rare disease portfolio and strengthening long-term growth potential beyond current products. This expansion enhances diversification and mitigates risks associated with portfolio concentration.

Despite a year-over-year net loss in Q2 2025, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reaffirmed guidance for 15–22% total revenue growth and anticipates positive GAAP net income in the second half of 2025. Strong sales traction for Galafold and growing adoption of Pombiliti + Opfolda are key drivers of this revenue growth.

Analysts remain positive on Amicus Therapeutics, Inc. (NASDAQ:FOLD), with price targets between $13 and $20, reflecting potential upside from its expanding rare disease franchise, pipeline development, and improving profitability. Firms like TD Cowen and Guggenheim maintain Buy ratings, highlighting the corporation’s strategic positioning and growth prospects.

While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.